Mapping the Evolutionary Landscape of Solid Tumor Immunotherapy: A Quarter-Century Bibliometric Analysis of the...

Cancer immunotherapy has evolved from an experimental niche to the established fourth pillar of oncological care. While the clinical success of checkpoint inhibitors is well-documented, the macro-level evolutionary trajectory of the field remains unmapped. This study provides a quarter-century bibliometric analysis of the core title-defined research landscape in solid tumor immunotherapy. Data from the Web of Science Core Collection were utilized as the primary source via a title-restricted search strategy, and core thematic structures were cross-compared against a high-impact Scopus subset. While this strategy ensures high clinical specificity, it represents a primary methodological limitation by inherently reducing search sensitivity and potentially excluding relevant studies with non-descriptive titles. The final data retrieval was conducted on January 1, 2026. The study covered the period from January 1, 2000, to December 31, 2025, utilizing advanced network visualization techniques via VOSviewer and Biblioshiny to identify spatiotemporal trends. 54,546 documents were identified, revealing a rapid and sustained expansion in publication volume, a descriptive trend that chronologically aligns with major clinical milestones such as the 2011 FDA approval of ipilimumab. Geopolitically, a distinctive divergence emerged: while China has surpassed the USA in total publication volume, the USA maintains higher integration in global collaboration networks and greater per-article citation counts. Network analysis visualized a decisive conceptual evolution from the "Cytokine Era" (2000-2010) to the "Checkpoint Revolution" (2011-2019). Most critically, recent trends (2020-2025) indicate a clear shift in research toward the "Tumor Microenvironment" and "Neoadjuvant Therapy" with the latter emerging as a predominant focus of recent translational research. The field's research focus is currently undergoing a structural transition from monotherapy in metastatic settings to combinatorial and perioperative strategies in early-stage disease. Current bibliometric trends indicate a growing academic focus on overcoming resistance mechanisms in "cold" tumors, reflecting strong translational interest in combining and sequencing immunotherapies with next-generation modalities, such as antibody-drug conjugates.